Biotechnology News and Research

RSS

Laser-induced breakdown spectroscopy emerges as fast, cost-efficient method for biomass analysis

Laser-induced breakdown spectroscopy (LIBS) is emerging as a fast, cost-efficient method for identifying the total amount and specific compounds that comprise the inorganic component of biomass. Accurate and reliable analysis of these minerals, such as aluminum, calcium, iron, and silicon is essential, as this "ash" can cause problems when converting biomass to hydrocarbon biofuels, as described in a study published in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

12 Jan 2016

Clontech Laboratories launches Guide-it CRISPR/Cas9 Gesicle Production System

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of the Guide-it CRISPR/Cas9 Gesicle Production System. This system provides an innovative method to deliver Cas9/single guide RNA (sgRNA) ribonucleoprotein complexes to a broad range of cell types.

11 Jan 2016

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology. Financial terms were not disclosed.

11 Jan 2016

Oxygen sensor PHD1 identified as potential target for treatment of ischemic stroke

Scientists at VIB and KU Leuven have identified the oxygen sensor PHD1 as a potential target for the treatment of brain infarction (ischemic stroke). Despite (minor) improvements in stroke treatment, stroke remains the fourth leading cause of death and the most common reason of severe disability.

8 Jan 2016

Experts develop technologies for protecting drinking water

We place high demands on the quality of our drinking water. If pathogens or toxic substances found their way into the piping system, many people could become infected or injured very quickly. That's why this risk must be kept low. To do this, experts have developed technologies for a comprehensive monitoring, early warning and emergency management system.

7 Jan 2016

Rutgers offers two-year fellowship program to enhance training of cancer surgeons

Aiming to enhance the training of cancer surgeons, a two-year fellowship program is now being offered by Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School. The Fellowship in Complex General Surgical Oncology offers board-eligible surgeons an opportunity to subspecialize in the intricacies of cancer care both in the clinical and research arenas.

7 Jan 2016

Leading researchers reject proposed link between adeno-associated virus 2 and hepatocellular carcinoma

The conclusion drawn from a recent study that insertion of adeno-associated virus 2 (AAV2) into human DNA causes mutations leading to the development of hepatocellular carcinoma (HCC) was resoundingly rejected by leading researchers in the fields of gene therapy and molecular genetics.

7 Jan 2016

Vtesse receives FDA's Breakthrough Therapy designation for VTS-270

Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.

6 Jan 2016

Study may hold new revelations about how stress during pregnancy affects mothers and offspring

The sequencing of the first genome involving a cockroach species may one day serve as a model system comparable to how research on mice can apply to humans. In this case, the model could hold new revelations about how stress during pregnancy could affect both the mother and her offspring.

6 Jan 2016

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).

5 Jan 2016

Amarantus seeks FDA's Rare Pediatric Disease Designation and ODD to treat GCMN with Engineered Skin Substitute

Amarantus BioScience Holdings, Inc., a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the US Food and Drug Administration to treat GCMN with Engineered Skin Substitute (ESS).

30 Dec 2015

Discovery Laboratories initiates AEROSURF phase 2b clinical trial in premature infants with RDS

Discovery Laboratories, Inc., a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has initiated its AEROSURF phase 2b clinical trial in premature infants 26 to 32 weeks gestational age (GA) receiving non-invasive nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS).

29 Dec 2015

UAB's Undiagnosed Diseases Program finds answers for mysterious health issues

Stephanie and Christopher Smith have been on a long, difficult and often frustrating journey to find answers for the mysterious health issues of their children. It started 24 years ago when their third child, Gage, was born. Gage, his younger brother Aiden and then sister Mandalynn, now 13, all developed mysterious symptoms that mystified doctors.

29 Dec 2015

ORIG3N to make debut appearance at 2015 CES Digital Health Summit

ORIG3N Inc., a biotechnology leading a transformation in the understanding and treatment of rare, genetically inherited diseases and a pioneer in regenerative medicine, announces its first appearance at the Digital Health Summit at CES, Jan. 6-9, 2016, in Las Vegas. ORIG3N will highlight AURA, FITCODE, and LifeCapsule, its innovative beauty and health technologies, at the conference.

29 Dec 2015

SUNY Downstate study maps areas of high probability of plague across the western US

Researchers at SUNY Downstate Medical Center have identified and mapped areas of high probability of plague bacteria in the western United States.

29 Dec 2015

Northwest Biotherapeutics closes registered direct placement of $12.6M

Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of its previously-announced registered direct placement with healthcare focused institutional investors, for gross proceeds of $12.6 million on the terms previously announced.

26 Dec 2015

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

Forge Therapeutics, Inc., a biotechnology company developing innovative medicines using a breakthrough drug discovery platform targeting metalloproteins, announced today it has obtained an exclusive license from the University of California San Diego to patent rights related to novel metalloprotein inhibitors discovered in the laboratory of Forge Therapeutics scientific co-founder Professor Seth Cohen, Ph.D.

22 Dec 2015

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Research that leads to improved therapies for Alzheimer's disease (AD) patients is one goal of Boston University School of Medicine professor of pharmacology and neurology Benjamin Wolozin, MD, PhD. He was one of six researchers awarded a two-year, $500,000 award in Alzheimer's Disease Drug Discovery Research by the Edward N. & Della L. Thome Memorial Foundation.

22 Dec 2015

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform.

21 Dec 2015

Biotechnology News and Research

Laser-induced breakdown spectroscopy emerges as fast, cost-efficient method for biomass analysis

Clontech Laboratories launches Guide-it CRISPR/Cas9 Gesicle Production System

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

Oxygen sensor PHD1 identified as potential target for treatment of ischemic stroke

Experts develop technologies for protecting drinking water

Rutgers offers two-year fellowship program to enhance training of cancer surgeons

Leading researchers reject proposed link between adeno-associated virus 2 and hepatocellular carcinoma

Vtesse receives FDA's Breakthrough Therapy designation for VTS-270

Study may hold new revelations about how stress during pregnancy affects mothers and offspring

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

Amarantus seeks FDA's Rare Pediatric Disease Designation and ODD to treat GCMN with Engineered Skin Substitute

Discovery Laboratories initiates AEROSURF phase 2b clinical trial in premature infants with RDS

UAB's Undiagnosed Diseases Program finds answers for mysterious health issues

ORIG3N to make debut appearance at 2015 CES Digital Health Summit

SUNY Downstate study maps areas of high probability of plague across the western US

Northwest Biotherapeutics closes registered direct placement of $12.6M

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News